8-K: Collegium Pharma Reports Record 2025 Results, Strong 2026 Outlook

Collegium Pharmaceutical, Inc. announced record full-year 2025 net revenues and adjusted EBITDA, driven by significant growth in Jornay PM and durable performance across its pain portfolio, while reaffirming strong 2026 guidance.

Summary

• Collegium Pharmaceutical, Inc. reported record full-year 2025 net revenues of $780.6 million, marking a 24% increase year-over-year.
• Full-year 2025 Adjusted EBITDA reached a record $460.5 million, up 15% year-over-year.
• Jornay PM net revenue for fiscal year 2025 grew by 48% year-over-year to $148.9 million.
• The pain portfolio generated record net revenues of $631.7 million for fiscal year 2025, an increase of 6% year-over-year.
• The company ended 2025 with a strong cash position, holding $386.7 million in cash, cash equivalents, and marketable securities.
• Full-year 2026 guidance was reaffirmed, projecting Product Revenues, Net between $805 million and $825 million, Jornay PM Revenue, Net between $190 million and $200 million, and Adjusted EBITDA between $455 million and $475 million.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong report, demonstrating robust growth in key products, effective capital management, and positive forward-looking guidance, despite some GAAP metric declines due to increased operating expenses.

Positives

• Record full-year 2025 net revenues of $780.6 million, a 24% increase year-over-year.
• Record full-year 2025 Adjusted EBITDA of $460.5 million, a 15% increase year-over-year.
• Jornay PM net revenue for FY 2025 grew 48% year-over-year to $148.9 million, demonstrating significant growth.
• Jornay PM prescriptions reached an all-time high in Q4 2025 with over 200,000 prescriptions (up 16% YoY) and over 760,000 for FY 2025 (up 20% YoY).
• Jornay PM prescribers reached an all-time high of 29,000 healthcare providers in Q4 2025 (up 21% year-over-year).
• Pain portfolio net revenues were a record $631.7 million for FY 2025, up 6% year-over-year, indicating durability.
• Successful closing of a $980 million syndicated credit facility in December 2025, which improved debt terms and is expected to result in meaningful annualized interest savings.
• Generated $329.3 million in cash from operations in FY 2025, highlighting strong cash flow generation.
• Repurchased $25 million of shares in 2025, contributing to $222 million returned to shareholders since 2021.
• Net debt to adjusted EBITDA was less than 1x at the end of 2025, indicating a strong financial profile.
• Hikma Pharmaceuticals USA Inc. launched an authorized generic of Nucynta, with Nucynta ER AG expected in Q1 2026, from which Collegium will receive a significant share of net profits.

Negatives

• Xtampza ER net revenue decreased by 6% year-over-year to $48.6 million in Q4 2025.
• GAAP net income for FY 2025 was $62.9 million, a decrease from $69.2 million in FY 2024.
• GAAP earnings per share (basic) for FY 2025 was $1.98, down from $2.14 in FY 2024.
• GAAP operating expenses increased by 37% year-over-year to $283.6 million for FY 2025.
• Adjusted operating expenses increased by 58% year-over-year to $237.3 million for FY 2025.

Risks

• Unknown liabilities could impact financial performance.
• Uncertainty regarding the expected financial performance of products.
• Ability to commercialize and grow sales of products may be challenged.
• Managing relationships with licensors is crucial for product availability.
• Success of competing products could erode market share.
• Maintaining regulatory approval of products and managing related restrictions, limitations, and/or warnings in labels.
• The size of the markets for products and the ability to service those markets.
• Ability to obtain reimbursement and third-party payor contracts for products.
• The rate and degree of market acceptance of products.
• Costs of commercialization activities, including marketing, sales, and distribution.
• Changing market conditions for products could affect demand.
• Outcome of any patent infringement or other litigation that may be brought by or against the company.
• Outcome of any governmental investigation related to the business.
• Ability to secure adequate supplies of active pharmaceutical ingredient for each product and manufacture adequate supplies of commercially saleable inventory.
• Ability to obtain funding for operations and business development.
• Regulatory developments in the U.S. could impact product approvals or market access.
• Ability to obtain and maintain sufficient intellectual property protection for products.
• Ability to comply with stringent U.S. and foreign government regulation in the manufacture of pharmaceutical products, including U.S. Drug Enforcement Agency compliance.
• Customer concentration could pose a risk.
• Accuracy of estimates regarding expenses, revenues, capital requirements, and need for additional financing.

Future Outlook

Collegium Pharmaceutical reaffirms its full-year 2026 guidance, projecting Product Revenues, Net between $805 million and $825 million, Jornay PM Revenue, Net between $190 million and $200 million, and Adjusted EBITDA between $455 million and $475 million. The company plans to drive further growth for Jornay PM, maximize the durability of its pain portfolio, and strategically deploy capital through business development, debt repayment, and share repurchases.

Management Comments

• "In 2025, we delivered on our strategic priorities by driving significant growth for Jornay PM, maximizing the durability of our pain portfolio, and strategically deploying capital." Vikram Karnani, President and Chief Executive Officer.
• "Our investments to expand the sales force and sharpen our marketing approach are already fueling additional momentum." Vikram Karnani, President and Chief Executive Officer.
• "These results, including solid performance across our pain portfolio, reflect more than a strong year of execution. They underscore the foundation we are building to drive sustained growth and deliver value for patients and shareholders." Vikram Karnani, President and Chief Executive Officer.
• "With a strengthened financial profile and a strong start to 2026, we are well positioned to build on this momentum and continue creating long-term value." Vikram Karnani, President and Chief Executive Officer.
• "Net revenues and adjusted EBITDA reached record highs in 2025, growing 24% and 15%, respectively, driven by strong performance from both Jornay PM and our pain portfolio." Colleen Tupper, Chief Financial Officer.
• "We generated significant operating cash flows, improved our debt terms, and repurchased $25 million of shares." Colleen Tupper, Chief Financial Officer.
• "In 2026, we expect another year of significant growth for Jornay PM and durable performance from our pain portfolio." Colleen Tupper, Chief Financial Officer.
• "We remain committed to our capital deployment strategy, prioritizing business development opportunities, opportunistic share repurchases, and paying down debt, all of which are intended to create long-term value." Colleen Tupper, Chief Financial Officer.

Industry Context

StockSavvy.ai notes that Collegium Pharmaceutical's strong performance in the ADHD and pain management sectors positions it well within the biopharmaceutical industry. The significant growth of Jornay PM highlights the demand for differentiated treatments in neuropsychiatry, while the durable performance of its pain portfolio, despite generic competition for Nucynta, demonstrates effective portfolio management. The strategic capital deployment, including debt refinancing and share repurchases, aligns with broader industry trends of optimizing capital structure and enhancing shareholder value.

Comparison to Industry Standards

• Jornay PM is rated as the #1 highest rated branded ADHD medicine in terms of product differentiation, with over 60% of surveyed HCPs planning to increase prescribing, indicating strong market acceptance compared to other branded ADHD medicines.
• Belbuca is rated as the #1 highest rated branded ER opioid in terms of product differentiation and favorability, with 74% of surveyed target HCPs planning to increase prescribing, suggesting a leading position in its segment.
• Xtampza ER is rated as the #1 highest rated ER oxycodone in terms of product differentiation and favorability, with 48% of surveyed target HCPs planning to increase prescribing, indicating strong competitive standing.
• The company's net debt to adjusted EBITDA ratio of less than 1x at the end of 2025 is a strong indicator of financial health and leverage management, often considered favorable compared to industry peers who may carry higher debt burdens.

Stakeholder Impact

• Shareholders: Positive impact due to record revenues, EBITDA growth, share repurchases, improved debt terms, and reaffirmed strong 2026 guidance, indicating potential for increased shareholder value.
• Patients/Caregivers: Positive impact through continued availability and growth of differentiated treatments like Jornay PM for ADHD and responsible pain management medications.
• Employees: Continued growth and expansion, particularly in the sales force for Jornay PM, suggests stable to growing employment opportunities.
• Creditors: Improved debt terms and a strong cash position enhance the company's creditworthiness.
• Suppliers: Continued product growth implies stable or increased demand for active pharmaceutical ingredients and manufacturing services.

Next Steps

• Drive further growth for Jornay PM through expanded sales force and sharpened marketing approach.
• Maximize the durability of the Pain Portfolio.
• Strategically deploy capital through business development opportunities, debt repayment, and opportunistic share repurchases.
• Participate in the Leerink Global Healthcare Conference on March 9, 2026, in Miami, FL.
• Participate in the Jefferies Biotech on the Beach Summit on March 10, 2026, in Miami, FL.
• Participate in the Citizens Life Sciences Conference on March 10, 2026, in Miami, FL.
• Participate in the Barclays 28th Annual Global Healthcare Conference on March 11, 2026, in Miami, FL.
• Expect the launch of Nucynta ER authorized generic by Hikma in Q1 2026.
• Participate in the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026.

Key Dates

Recommendation

The company delivered record full-year 2025 financial results, significantly driven by the robust growth of Jornay PM and a resilient pain portfolio. The reaffirmation of strong 2026 guidance, coupled with a strengthened balance sheet, disciplined capital deployment strategy (including share repurchases and debt optimization), and a low net debt to adjusted EBITDA ratio, indicates strong operational execution and a clear path for continued value creation. The strategic focus on neuropsychiatry and pediatrics, alongside maximizing the pain portfolio's durability, positions the company for sustained long-term growth and profitability, making it an attractive investment.

Keywords

Collegium Pharmaceutical, COLL, Financial Results, Earnings, ADHD, Jornay PM, Pain Management, Belbuca, Xtampza ER, Nucynta, Biopharmaceutical, Pharmaceutical, Revenue Growth, EBITDA, Credit Facility, Share Repurchase, Neuropsychiatry, Q4 2025, FY 2025, 2026 Guidance